BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10030621)

  • 1. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer.
    Iannuzzi CM; Stock RG; Stone NN
    Radiat Oncol Investig; 1999; 7(1):30-5. PubMed ID: 10030621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression].
    Almeras C; Zerbib M; Eschwege F; Debré B
    Prog Urol; 2002 Apr; 12(2):219-25. PubMed ID: 12108335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
    Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
    Ragde H; Korb LJ; Elgamal AA; Grado GL; Nadir BS
    Cancer; 2000 Jul; 89(1):135-41. PubMed ID: 10897010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation.
    Buyyounouski MK; Hanlon AL; Horwitz EM; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1291-8. PubMed ID: 15817330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer.
    Cavanagh W; Blasko JC; Grimm PD; Sylvester JE
    Semin Urol Oncol; 2000 May; 18(2):160-5. PubMed ID: 10875459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.